Physicians, advocates call for expanding indications for off-label drugs

March 2011
Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p1
Academic Journal
The article reports on the advocacy of the Alliance of Specialty Medicine in the U.S. to expand indication for off-label drugs and support the distribution of product information to clinicians, but maintain the illegality of marketing products for off-label uses.


Related Articles

  • What You May Not Know About Your Medicine.  // Consumer Reports on Health;Mar2016, Vol. 28 Issue 3, p9 

    The article examines whether off-label prescribing of drugs by doctors for unapproved uses is a safe practice. Topics covered include thoughts from Gordon Schiff, M.D., of the Center for Patient Safety Research and Practice on off-label prescribing, drugs that are commonly prescribed off-label...

  • “Right to Try” laws. Begg, Colin B; Kim, KyungMann; Neaton, James D // Clinical Trials;Oct2014, Vol. 11 Issue 5, p519 

    No abstract available.

  • Physicians, advocates call for expanding indications for off-label drugs. Hasson, Matt; Durrie, Daniel S.; Hovanesian, John A.; MacHatton, Doug; Muilenburg, Crystal // Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p54 

    The article reports that the Alliance of Specialty Medicine urges the expansion of indications for approved drugs used as off label products in response to the federal law which prohibits manufacturers to promote off-label use of the products. It says that the group believes that physicians can...

  • Clinical outcome data for off-label medications: The more the better. Psooy, Karen // Canadian Urological Association Journal;mar/avr2014, Vol. 8 Issue 3/4, p124 

    The author discusses the prescription of off-label drugs by the urologists treating overactive bladder in children rather than those which are approved by government body Health Canada or U.S. Food and Drug Administration. He states that they must be confident while recommending off-label drugs,...

  • Off Label, But on Target. Murphy, John // Review of Optometry;12/15/2015, Vol. 152 Issue 12, p46 

    The article discusses off-label or those drugs not approved by the United States Food and Drug Administration (FDA) for use in eye care and treatment. It includes Restasis for inflammatory condition such as uveitis, oral ibuprofen in place of steroids for anterior uveitic inflammation, Lotemax...

  • Strategy to address innovative off-label medication use in China: grading management. Hanbin Wu; Gao Wu // European Journal of Clinical Pharmacology;Oct2014, Vol. 70 Issue 10, p1271 

    A letter to the editor is presented which is concerned with the off label use of medications in China.

  • FDA sees no significant effect on enforcement, drops Caronia case. McCARTY, MARK // Medical Device Daily;1/25/2013, Vol. 17 Issue 17, p1 

    The article reports on the decision of the U.S. Food and Drugs Administration (FDA) in not pursuing the case U.S. v. Caronia. It notes that the case will bear no significant impact on FDA's misbranding regulations. It also mentions the decision of the Court of Appeals for the Second Circuit...

  • A Tale of Two Citizens: A State Attorney General and a Hematologist Facilitate Translation of Research Into US Food and Drug Administration Actions-A SONAR Report. Bennett, Charles L.; Chen, Brian; Restaino, John; Norris, Leann; Xirasagar, Sudha; Qureshi, Zaina P.; Mckoy, June M.; Lopez, Isaac S.; Trenery, Alyssa; Murday, Alanna; Kahn, Adam; Mattison, Donald R.; Ray, Paul; Sartor, Oliver // Journal of Oncology Practice;Nov2012, Vol. 8 Issue 6, pe158 

    Purpose: Pharmaceutical safety is a public health issue. In 2005, the Connecticut Attorney General (AG) raised concerns over adverse drug reactions in off-label settings, noting that thalidomide was approved to treat a rare illness, but more than 90% of its use was off label. A hematologist had...

  • Topiramate: Antipsychotic-Induced Weight Gain. Generali, Joyce A.; Cada, Dennis J. // Hospital Pharmacy;Apr2014, Vol. 49 Issue 4, p345 

    This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide...


Read the Article


Sign out of this library

Other Topics